Teva Pharmaceutical Industries (TEV) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Teva Pharmaceutical: Teva Takes on Antimicrobial Resistance: What You Need to KnowNovember 21 at 11:18 PM | finanznachrichten.deTeva Pharmaceutical Strengthens Board with New AppointmentNovember 14, 2024 | markets.businessinsider.comTeva Reports Strong Q3 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comTeva sees FY24 EPS $2.40-$2.50, consensus $2.45November 6, 2024 | markets.businessinsider.comGeneric Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual ForecastNovember 6, 2024 | benzinga.comSevere Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightNovember 6, 2024 | finance.yahoo.comTeva gains after raising outlook for second time this yearNovember 6, 2024 | msn.comTeva Pharmaceutical sees more growth in 2025 after strong Q3November 6, 2024 | msn.comTeva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | finance.yahoo.comTeva Pharmaceutical third-quarter profit, revenue top estimatesNovember 6, 2024 | reuters.comTeva presents Phase 3 SOLARIS trial resultsNovember 2, 2024 | markets.businessinsider.comTeva long-acting olanzapine shows improvements in schizophrenia patientsNovember 1, 2024 | msn.comTeva fined $500M by EU for disparaging rival MS drug (update)November 1, 2024 | seekingalpha.comEU Commission Fines Teva $500 Million for Trying to Stop Rival's Multiple Sclerosis DrugOctober 31, 2024 | msn.comTeva Fined Around $500 Million by EU Over MS Drug Competition ConcernsOctober 31, 2024 | wsj.comTeva Hit With €463 Million EU Fine for Talking Down RivalsOctober 31, 2024 | bloomberg.comFDA approves Alvotech and Teva’s SELARSDI for new indicationsOctober 23, 2024 | msn.comTeva Pharmaceutical (TEVA) Receives a Buy from BarclaysOctober 23, 2024 | markets.businessinsider.comTeva price target raised to $25 from $22 at BarclaysOctober 23, 2024 | markets.businessinsider.comTeva call volume above normal and directionally bullishOctober 22, 2024 | markets.businessinsider.comTeva Pharmaceutical Industries Limited (TEVA): A Bull Case TheoryOctober 22, 2024 | finance.yahoo.comTeva, Alvotech announce U.S. FDA approval of presentation of SELARSDIOctober 22, 2024 | markets.businessinsider.comTeva, Alvotech get expanded FDA approval for Stelara biosimilarOctober 22, 2024 | seekingalpha.comAlvotech And Teva Pharmaceuticals Announce Expansion Of SELARSDI's IndicationsOctober 22, 2024 | markets.businessinsider.comTeva Pharmaceutical (TEVA) Receives a Buy from UBSOctober 16, 2024 | markets.businessinsider.comTeva Pharma To Pay $450 Mln To Settle Kickback AllegationsOctober 11, 2024 | markets.businessinsider.comTeva to pay $450 million to resolve US kickback, price-fixing casesOctober 10, 2024 | msn.comTeva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...October 9, 2024 | finance.yahoo.comPharma company funding for patient advocacy groups needs to be transparent, says researcherOctober 3, 2024 | msn.comTeva Arm Inks New Licensing PactOctober 3, 2024 | baystreet.caTeva, MAbxience Enter Licensing Deal For Development Of Anti PD-1 Oncology Biosimilar CandidateOctober 3, 2024 | markets.businessinsider.comTeva Pharma Launches Octreotide Acetate For Injectable Suspension - Quick FactsOctober 1, 2024 | markets.businessinsider.comTeva Launches Generic Version Of Sandostatin In The USOctober 1, 2024 | benzinga.com$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much TodaySeptember 30, 2024 | benzinga.comEpinephrine Autoinjectors Industry Research Business Report 2024 Featuring ALK-Abello, Bausch + Lomb, Emerade, Teva PharmaceuticalSeptember 26, 2024 | finance.yahoo.comJefferies Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)September 24, 2024 | markets.businessinsider.comTeva Pharmaceutical (TEVA) Gets a Buy from BarclaysSeptember 24, 2024 | markets.businessinsider.comTeva touts safety profile of once monthly schizophrenia therapySeptember 23, 2024 | finance.yahoo.comTeva : New Data Offer Insights On Switching Schizophrenia Patients To UZEDY From PerserisSeptember 21, 2024 | markets.businessinsider.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) is favoured by institutional owners who hold 68% of the companySeptember 15, 2024 | finance.yahoo.comTeva Pharmaceutical Industries Ltd: Teva to Present at the Bank of America 2024 Global Healthcare ConferenceSeptember 11, 2024 | finanznachrichten.deExclusive-Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources saySeptember 11, 2024 | msn.comTeva Set to Be Hit By EU Antitrust Fine for Talking Down RivalsSeptember 11, 2024 | msn.comTeva Pharmaceuticals to pay Baltimore $80M to settle opioid lawsuitSeptember 9, 2024 | yahoo.comBaltimore City to receive $80 million in Teva Pharmaceuticals opioid settlementSeptember 9, 2024 | cbsnews.comUBS Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)September 9, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)September 9, 2024 | markets.businessinsider.comKey Takeaways From Teva Pharmaceutical Indus Analyst RatingsSeptember 3, 2024 | benzinga.comTeva- Pharmaceutical Industries LtdAugust 29, 2024 | 247wallst.comPiper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)August 29, 2024 | markets.businessinsider.com Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. TEV Media Mentions By Week TEV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TEV News Sentiment▼0.000.50▲Average Medical News Sentiment TEV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TEV Articles This Week▼13▲TEV Articles Average Week Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genfit News Merck KGaA News MorphoSys News ad pepper media International News Evotec News Fielmann Group News Fresenius SE & Co. KGaA News Sanofi News Sartorius Stedim Biotech News Siemens Healthineers News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (FRA:TEV) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
